| Identification | |
| Name: | Travoprost |
| Synonyms: | 5-Heptenoicacid,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-,1-methylethyl ester, (5Z)- (9CI);5-Heptenoic acid,7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-,1-methylethyl ester, [1R-[1a(Z),2b(1E,3R*),3a,5a]]-;AL 6221;Travatan; |
| CAS: | 157283-68-6 |
| Molecular Formula: | C26H35F3O6 |
| Molecular Weight: | 500.55 |
| InChI: | InChI=1/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3+,13-12+/t19?,21-,22-,23+,24-/m1/s1 |
| Molecular Structure: | ![(C26H35F3O6) 5-Heptenoicacid,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1...](https://img.guidechem.com/casimg/157283-68-6.png) |
| Properties | |
| Transport: | UN 1170 3 |
| Density: | 1.245 g/cm3 |
| Refractive index: | 1.547 |
| Appearance: | colorless oil |
| Specification: |
Travoprost (CAS NO.157283-68-6) is also named as (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester ; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester ; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate ; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))- ; AL-6221 ; AL6221 ; Travatan ; Travatan Z ; UNII-WJ68R08KX9 . Travoprost (CAS NO.157283-68-6) is colorless oil. |
| Storage Temperature: | −20°C |
| Usage: |
Travoprost (CAS NO.157283-68-6) can be used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. |
| Safety Data | |
 |
|
